| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q08HX018 (ip) | median survival time | saline | 31.25 micrograms/kg/injection | 123.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q08HX018 (ip) | median survival time | saline | 62.5 micrograms/kg/injection | 122.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q08HX018 (ip) | median survival time | saline | 125.0 micrograms/kg/injection | 127.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q08HX018 (ip) | median survival time | saline | 250.0 micrograms/kg/injection | 140.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q08HX018 (ip) | median survival time | saline | 500.0 micrograms/kg/injection | 169.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q08HX018 (ip) | median survival time | saline | 1000.0 micrograms/kg/injection | 225.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q08HX018 (ip) | median survival time | saline | 2000.0 micrograms/kg/injection | 98.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 1.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 1.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2.5 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.6 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.6 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 9; 06/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.3 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.3 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 7.2 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 7.2 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 194.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 196.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 5; 04/05 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 9; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 9; 06/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 9; 06/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 16.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 16.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 16.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 9; 00/04 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 58.0 | Antitumor endpoint evaluated on day 9; 08/00 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 9; 02/05 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 9; 06/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 82.0 | Antitumor endpoint evaluated on day 9; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 24.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 07/10 animals surviving on day 5 |
| Q01DX001 (sc) | median survival time | saline | 1.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (sc) | median survival time | saline | 2.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (sc) | median survival time | saline | 4.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (sc) | median survival time | saline | 8.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (sc) | median survival time | saline | 16.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 1.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 2.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 4.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 8.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 8.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 16.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 07/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 2.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 4.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 8.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 16.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 32.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 32.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 64.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 08/10 animals surviving on day 5 |
| Q01DX001 (oral) | median survival time | saline | 128.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/10 animals surviving on day 5 |
| Q01DX001 (im) | median survival time | saline | 1.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (im) | median survival time | saline | 2.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (im) | median survival time | saline | 4.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (im) | median survival time | saline | 8.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX001 (im) | median survival time | saline | 16.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.38 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.38 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.75 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.75 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 0.86 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.4 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline | 1.5 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 1.5 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 267.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 2.4 mg/kg/injection | 234.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline | 3.0 mg/kg/injection | 244.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 3.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 4.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 8.0 mg/kg/injection | 237.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 208.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 285.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 419.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 368.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 533.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.32 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.32 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.32 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.4 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 220.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.63 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.63 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.63 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.8 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 251.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 227.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 245.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 04/05 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 224.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 35; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 199.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 218.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 194.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 202.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.25 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.25 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.25 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.6 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 241.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 243.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 282.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 274.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 253.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 224.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 247.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 230.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 233.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 231.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 268.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 252.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 238.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 227.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 233.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 227.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 353.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 327.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 267.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 243.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 279.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 204.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 252.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 241.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 268.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 264.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 194.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 220.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 266.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 256.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 250.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 247.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 260.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 206.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 282.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 282.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 316.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 287.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.5 mg/kg/injection | 227.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 3.2 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 6.4 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 05/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 62.5 micrograms/kg/injection | 118.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 125.0 micrograms/kg/injection | 116.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 250.0 micrograms/kg/injection | 122.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 500.0 micrograms/kg/injection | 140.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1000.0 micrograms/kg/injection | 169.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2000.0 micrograms/kg/injection | 252.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4000.0 micrograms/kg/injection | 169.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 1.3 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 2.0 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 3.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 4.5 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.25 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 0.5 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 204.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 1.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/04 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/04 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 1.3 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 1.3 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 1.94 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 1.94 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 2.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (ip) | median survival time | saline | 2.16 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 2.16 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.24 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.24 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.6 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.6 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 4.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (ip) | median survival time | saline | 5.4 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 5.4 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 6.0 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 6.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 8.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (ip) | median survival time | saline | 9.0 mg/kg/injection | 287.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 9.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 10.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 15.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 07/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 15.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 16.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 9; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 36; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.63 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 0.75 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 0.75 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 55; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 0.75 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 0.75 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 0.97 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 10; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.04 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 45; 06/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 36; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 9 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 55; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.5 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.62 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.62 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.73 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 45; 07/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 10; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 202.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 36; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 214.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 247.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 9 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.7 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.7 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.88 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.0 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 55; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 213.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 210.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 247.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 252.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 245.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 237.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 231.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 48; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 213.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 44; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 251.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 10; 06/07 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 9; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 199.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 196.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.5 mg/kg/injection | 295.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.5 mg/kg/injection | 259.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.8 mg/kg/injection | 308.0 | Antitumor endpoint evaluated on day 45; 07/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 218.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 237.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 255.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 250.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 250.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 277.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 242.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 252.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 245.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 267.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 9 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 210.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 265.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 204.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 301.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 284.0 | Antitumor endpoint evaluated on day 36; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 279.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 351.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 284.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 299.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 271.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 268.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 267.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 234.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 252.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 273.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 252.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 220.0 | Antitumor endpoint evaluated on day 48; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 321.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 327.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 330.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 295.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 287.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 297.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 280.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 316.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 353.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 233.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 220.0 | Antitumor endpoint evaluated on day 44; 09/09 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 268.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 267.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 323.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 304.0 | Antitumor endpoint evaluated on day 55; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 336.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 259.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 7.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 45; 07/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 7.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 224.0 | Antitumor endpoint evaluated on day 10; 06/07 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 254.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 242.0 | Antitumor endpoint evaluated on day 47; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 47; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 44; 09/09 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 306.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 354.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 348.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 420.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 485.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 323.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 413.0 | Antitumor endpoint evaluated on day 60; 09/09 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 612.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 392.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 310.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 377.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 265.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 440.0 | Antitumor endpoint evaluated on day 48; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 321.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 330.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 368.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 560.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 288.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 271.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 206.0 | Antitumor endpoint evaluated on day 9; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 256.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 347.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 9 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 214.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 36; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 12.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 12.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 12.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 55; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 12.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 16.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 16.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 9 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 1.8 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.3 mg/kg/injection | 196.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 8; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 10; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 10; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 240.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 10; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 248.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 8; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 10; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 7; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 239.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 326.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 290.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 10; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 292.0 | Antitumor endpoint evaluated on day 5; 09/09 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 7; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 8; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 10; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 243.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 264.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 408.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 218.0 | Antitumor endpoint evaluated on day 8; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 10; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 218.0 | Antitumor endpoint evaluated on day 7; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 471.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 9.0 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 10; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 1.25 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (iv) | median survival time | saline | 2.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 4.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 8.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 16.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (oral) | median survival time | saline | 8.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (oral) | median survival time | saline | 16.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (oral) | median survival time | saline | 32.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (oral) | median survival time | saline | 64.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |